- RESEARCH HIGHLIGHT
Macrocyclic peptides challenge cell cycle defects
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
doi: https://doi.org/10.1038/d41573-025-00162-3
References
Singh, S. et al. Targeting G1–S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors. Nature https://doi.org/10.1038/s41586-025-09433-w (2025).